The trading platform RoboMarkets has significantly widened its offering, adding more than 1,300 U.S.-listed stocks and exchange-traded funds (ETFs) in a move that increases its total catalog to over 8,000 instruments.
The new assets, listed on the NASDAQ and New York Stock Exchange, are intended to provide clients with deeper exposure to key sectors of the world’s largest financial market. The expansion includes companies from the technology, financial services, energy and healthcare industries, such as Microchip Technology, Morgan Stanley Direct Lending Fund and the biopharmaceutical firm Valneva. Several income and convertible funds from major asset managers are also newly available.
The company emphasized that trading these U.S. instruments will be commission-free, with real-time market data provided at no extra cost. Its pricing model adds a small markup to the market spread, which it says can be as low as 0.15%.
Alongside the market expansion, RoboMarkets has introduced several platform upgrades. Its integration with the analysis platform TradingView has been enhanced, now providing charting coverage for a wider range of European and U.S. securities.
Meanwhile, Bloomberg has strengthened its financial data offerings in Australia by streamlining its pricing tools to better serve the country’s expanding fixed-income sector. This initiative marks the first time investors have access to a unified source of information for Australian bonds.
As part of the update, Bloomberg’s BVAL evaluated pricing service now includes 600 Australian asset-backed securities (ABS), extending its coverage beyond the existing 1,600 residential mortgage-backed securities (RMBS) and corporate bonds. The expanded dataset enables traders to more effectively assess valuations and risk across a broader spectrum of debt instruments.
Read more: How Athena Edge Plans to Become a Legacy Brand — Interview With Founder Alex Mustatea
Disclaimer: The content presented herein is for informational purposes only. While efforts have been made to ensure the accuracy of the information, no guarantees are made regarding its completeness, reliability or suitability for any particular purpose. Before making any financial decisions, we strongly advise seeking guidance from a qualified professional.
